Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19 study - Obe-cel response and safety data from the Phase 1b portion of the FELIX study...
June 11, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress

Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade...
May 12, 2021 10:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress

AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients No high-grade cytokine release syndrome or neurotoxicity observed LONDON, May 12, 2021 ...
November 06, 2019 09:24 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 61st ASH Annual Meeting

LONDON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
April 01, 2019 13:05 ET | Source: Autolus Therapeutics plc

Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting

Initial results from the trial show 88% molecular complete response at one month with well-tolerated safety profile Management to Hold Conference Call on April 2, 2019 at 8:00am ET / 1:00pm BST ...
March 29, 2019 16:03 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019

LONDON, March 29, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...